The Use of the Selective Imidazoline I
Imidazoline I1 receptor agonist
astrocytes
carbophenyline
chemotherapy-induced neuropathic pain
oxaliplatin
Journal
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
ISSN: 1878-7479
Titre abrégé: Neurotherapeutics
Pays: United States
ID NLM: 101290381
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
pubmed:
24
6
2020
medline:
2
9
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
Anti-cancer therapy based on the repeated administration of oxaliplatin is limited by the development of a disabling neuropathic syndrome with detrimental effects on the patient's quality of life. The lack of effective pharmacological approaches calls for the identification of innovative therapeutic strategies based on new targets. We focused our attention on the imidazoline I
Identifiants
pubmed: 32572830
doi: 10.1007/s13311-020-00873-y
pii: 10.1007/s13311-020-00873-y
pmc: PMC7609613
doi:
Substances chimiques
Antineoplastic Agents
0
Imidazoles
0
Imidazoline Receptors
0
imidazoline I1 receptors
0
Oxaliplatin
04ZR38536J
imidazole
7GBN705NH1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1005-1015Références
International Association for the Study of Pain. IASP Taxonomy. Pain terms. Neuropathic pain. Updated 2017. www.iasp-pain.org/Taxonomy#Neuropathicpain
André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343–51.
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
Beijers AJM, Mols F, Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer. 2014;22:1999–2007.
Balayssac D, Ferrier J, Descoeur J, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf. 2011;10:407–17.
Kiernan MC. The pain with platinum: oxaliplatin and neuropathy. Eur J Cancer. 2007;43:2631-2633.
Argyriou AA, Cavaletti G, Briani C, et al. Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer. Cancer. 2013;119(2):438-44.
Ta LE, Espeset L, Podratz J, Windebank AJ. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicol. 2006;27:992-1002.
Di Cesare Mannelli L, Pacini A, Bonaccini L, Zanardelli M, Mello T, Ghelardini C. Morphologic features and glial activation in rat oxaliplatin-dependent neuropathic pain. J Pain. 2013;14:1585-600.
Di Cesare Mannelli L, Pacini A, Micheli L, Tani A, Zanardelli M, Ghelardini C. Glial role in oxaliplatin-induced neuropathic pain. Exp Neurol. 2014;261:22-33.
Di Cesare Mannelli L, Pacini A, Matera C, et al. Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacol. 2014;79:37-48.
Di Cesare Mannelli L, Marcoli M, Micheli L, et al. Oxaliplatin evokes P2X7-dependent glutamate release in the cerebral cortex: A pain mechanism mediated by Pannexin 1. Neuropharmacol. 2015;97:133-41.
Ibrahim EY, Ehrlich BE. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings. Crit Rev Oncol Hematol. 2020;145:102831.
Hershman DL, Lacchetti C, Loprinzi CL. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2014;10(6):e421-e424.
Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev. 2014;40(7):872-82.
Alemany R, Olmos G, GarciaSevilla JA. Labelling I-2B-imidazoline receptors by [H-3]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn-Schmied. Arch Pharmacol. 1997;356:39-47.
Gentili F, Cardinaletti C, Carrieri A, et al. Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects. Eur J Pharmacol. 2006;553:73–81.
Li JX, Thorn DA, Qiu Y, Peng BW, Zhang Y. Antihyperalgesic effects of imidazoline I
Bektas N, Nemutlu D, Arsla R. The imidazoline receptors and ligands in pain modulation. Indian J Pharmacol. 2015;47:472-478.
Thorn DA, Zhang Y, Li JX. Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I2 receptor agonist phenyzoline in adult male rats. Psychopharmacol. 2017;234:1871-1880.
Nikolic K, Agbaba D. Pharmacophore development and SAR studies of imidazoline receptor ligands. Mini-Rev Med Chem. 2012;12:1542−1555.
Cobos-Puc L, Aguayo-Morales H. Cardiovascular Effects Mediated by Imidazoline Drugs: An Update. Cardiovasc Hematol Disord Drug Targets. 2019;19(2):95-108.
Head GA, Burke SL. I1 imidazoline receptors in cardiovascular regulation: the place of rilmenidine. Am J Hypertens. 2000;13:89S–98S.
Ernsberger P. The I1-imidazoline receptor and its cellular signaling pathways. Ann N Y Acad Sci. 1999;881:35–53.
Musgrave IF, Hughes R. 1999. Novel targets and techniques in imidazoline receptor research. Ann N Y Acad Sci. 1999;881:217–228.
Greney H, Ronde P, Magnier C, et al. Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline. Mol Pharmacol. 2000;57:1142–1151.
Yoro SG, Urosevic D, Fellmann L, Greney H, Bousquet P, Feldman J. G-protein inwardly rectifying potassium channels are involved in the hypotensive effect of I1-imidazoline receptor selective ligands. J Hypertens. 2008;26:1025–1032.
Kim YH, Nam TS, Ahn DS, Chung S. Modulation of N-type Ca(2)(+) currents by moxonidine via imidazoline I(1) receptor activation in rat superior cervical ganglion neurons. Biochem Biophys Res Commun. 2011;409:645–650.
Harraz OF, El-Gowelli HM, Mohy El-Din MM, Ghazal AR, El-Mas MM. Adenosinergic modulation of the imidazoline I(1)- receptor-dependent hypotensive effect of ethanol in acute renal failure. Food Chem Toxicol. 2012;50:2622–2628.
Gentili F, Bousquet P, Carrieri A, et al. Rational design of the new antihypertensive I
Del Bello F, Bargelli V, Cifani C, et al. Antagonism/agonism modulation to build novel antihypertensives selectively triggering I
Gentili F, Bousquet P, Brasili L, et al. Imidazoline Binding Sites (IBS) profile modulation: key role of the bridge in determining I
Eglen RM, Hudson AL, Kendall DA, et al. “Seeing through a glass darkly”: casting light on imidazoline “I” sites. Trends Pharmacol Sci. 1998;19:381-390.
Hudson AL, Gough R, Tyacke R, et al. Novel selective compounds for the investigation of imidazoline receptors. Ann N Y Acad Sci. 1999;881:81-91.
McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP. Br J Pharmacol. 2015;172:3189–3193.
Cavaletti GG, Tredici MG, Petruccioli E, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer. 2001;37:2457-2463.
Micheli L, Di Cesare Mannelli L, Rizzi A, et al. 2015. Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity. Eur J Pharmacol. 2015;766:155-62.
Tanabe M, Takasu K, Takeuchi Y, Ono H. Pain relief by gabapentin and pregabalin via supraspinal mechanisms after peripheral nerve injury. J Neurosci Res. 2008;86(15):3258-64.
Russo R, D'Agostino G, Mattace Raso G, et al. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides. 2012;38(1):81-8.
Baptista-De-Souza D, Di Cesare Mannelli L, Zanardelli M, et al. Serotonergic modulation in neuropathy induced by oxaliplatin: effect on the 5HT2C receptor. Eur J Pharmacol. 2014;735:141-9.
Sakurai M, Egashira N, Kawashiri T, Yano T, Ikesue H, Oishi R. Oxaliplatin-induced neuropathy in the rat: involvement of oxalate in cold hyperalgesia but not mechanical allodynia. Pain. 2009;147:165–174.
Di Cesare Mannelli L, Micheli L, Maresca M, et al. Anti-neuropathic effects of Rosmarinus officinalis L. terpenoid fraction: relevance of nicotinic receptors. Sci Rep. 2016;6:34832
Cardinaletti C, Mattioli L, Ghelfi F, et al. Might adrenergic α
Del Bello F, Diamanti E, Giannella M, et al. Low doses of allyphenyline and cyclomethyline, effective against morphine dependence, elicit antidepressant-like effect. ACS Med Chem Lett. 2012;3:535-539.
Del Bello F, Giannella M, Piergentili A, Quaglia W. The 2-substituted imidazoline ring linked to an aromatic moiety by a biatomic bridge: a bioversatile scaffold. Glob Drugs Therap. 2016;1:1-4.
Giusepponi ME, Cifani C, Micioni Di Bonaventura MV, et al. Combined interactions with I
Gentili F, Bousquet P, Brasili L, et al. α
Del Bello F, Cilia A, Carrieri A, et al. The versatile 2-substituted imidazoline nucleus as a structural motif of ligands directed to the serotonin 5-HT
Di Cesare Mannelli L, Ghelardini C, Micheli L, et al. Synergic stimulation of serotonin 5-HT
Eisenach JC, DuPen S, Dubois M, Miguel R, Allin D. Epidural clonidine analgesia for intractable cancer pain. The Epidural Clonidine Study Group. Pain. 1995;61:391-9.
Pan HL, Chen SR, Eisenach JC. Role of spinal NO in antiallodynic effect of intrathecal clonidine in neuropathic rats. Anesthesiology. 1998;89:1518-23.
Szabo B. Imidazoline antihypertensive drugs: a critical review on their mechanism of action. Pharmacol Ther. 2002;93(1):1-35.
Wrzosek A, Woron J, Dobrogowski J, Jakowicka-Wordliczek J, Wordliczek J. Topical clonidine for neuropathic pain. Cochrane Database Syst Rev. 2015;318:CD010967.
Stone LS, Kitto KF, Eisenach JC, Fairbanks CA, Wilcox GL. ST91 [2-(2,6-diethylphenylamino)-2-imidazoline hydrochloride]-mediated spinal antinociception and synergy with opioids persists in the absence of functional alpha-2A- or alpha-2C-adrenergic receptors. J Pharmacol Exp Ther. 2007;323:899–906.
Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev. 2020;72:50-79.
Ernsberger P, Shen IH. Membrane localization and guanine nucleotide sensitivity of medullary I
Edwards L, Ernsberger P. The I(1)-imidazoline receptor in PC12 pheochromocytoma cells reverses NGF-induced ERK activation and induces MKP-2 phosphatase. Brain Res. 2003;980:71–79.
Alles SRA, Smith PA. Etiology and Pharmacology of Neuropathic Pain. Pharmacol Rev. 2018;70:315-347.
Coppi E, Cherchi F, Fusco I, et al. Adenosine A3 receptor activation inhibits pronociceptive N-type Ca2+ currents and cell excitability in dorsal root ganglion neurons. Pain. 2019;160:1103-1118.
Tanabe M, Kino Y, Honda M, Ono H. Presynaptic I
Dixit MP, Upadhya MA, Taksande B, et al. Neuroprotective effect of agmatine in mouse spinal cord injury model: Modulation by imidazoline receptors. J Nat Sci Biol Med. 2018;9:115-120.
Gupta S, Sharma B. Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain Res Bull. 2014;102:57-68.
Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009;10(1):23-36.
Von Hehn CA, Baron R, Woolf CJ. Deconstructing the Neuropathic Pain Phenotype to Reveal Neural Mechanisms. Neuron. 2012;73(4):638–652.
Jacob A, Hack B, Chiang E, Garcia JG, Quigg RJ, Alexander JJ. C5a alters blood-brain barrier integrity in experimental lupus. FASEB J. 2010;24(6):1682-8.
Nikolic K, Veljkovic N, Gemovic B, Srdic-Rajic T, Agbaba D. Imidazoline-1 receptor ligands as apoptotic agents: pharmacophore modeling and virtual docking study. Comb Chem High Throughput Screen. 2013;16:298-319
Sharma V, Peddibhotla S, Tepe JJ. Sensitization of cancer cells to DNA damaging agents by imidazolines. J Am Chem Soc. 2006;128:9137-43.
Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain. 2014;155:2461–2470.